<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>2</title>
<title_fa>1</title_fa>
<short_title>3</short_title>
<subject>Literature &amp; Humanities</subject>
<web_url>http://idai.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>9</journal_id_issn>
<journal_id_issn_online>10</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>7</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>fa</language>
<pubdate>
	<type>jalali</type>
	<year>1390</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2012</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>8</volume>
<number>8</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>fa</language>
	<article_id_doi></article_id_doi>
	<title_fa>MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma</title_fa>
	<title></title>
	<subject_fa>جراحی دهان، فک و صورت</subject_fa>
	<subject>Oral and Maxillofacial Surgery</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research</content_type>
	<abstract_fa>&lt;p&gt; &lt;strong&gt;Objectives&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;  Differences among cancer cells within a tumor are important in tumorigenesis and treatment resistance, yet no measure of intratumor heterogeneity is suitable for routine application. We developed a quantitative measure of intratumor genetic heterogeneity, based on differences among mutated loci in the mutant-allele fractions determined by next-generation sequencing (NGS) of tumor DNA. We then evaluated the application of this measure to head and neck squamous cell carcinoma (HNSCC). &lt;/p&gt;&lt;p&gt; &lt;strong&gt;Materials and methods&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;  We analyzed published electronically available NGS results for 74 HNSCC. For each tumor we calculated mutant-allele tumor heterogeneity (MATH) as the ratio of the width to the center of its distribution of mutant-allele fractions among tumor-specific mutated loci. &lt;/p&gt;&lt;p&gt; &lt;strong&gt;Results&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;  Intratumor heterogeneity assessed by MATH was higher in three poor-outcome classes of HNSCC: tumors with disruptive mutations in the TP53 gene (versus wild-type TP53 or non-disruptive mutations), tumors negative versus positive for human papillomavirus (even when restricted to tumors having wild-type TP53), and HPV-negative tumors from smokers with more pack-years of cigarette exposure (with TP53 status taken into account). &lt;/p&gt;&lt;p&gt; &lt;strong&gt;Conclusion&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;  The relation of this type of intratumor heterogeneity to HNSCC outcome classes supports its further evaluation as a prognostic biomarker. As NGS of tumor DNA becomes widespread in clinical research and practice, MATH should provide a simple, quantitative, and clinically practical biomarker to help evaluate relations of intratumor genetic heterogeneity to outcome in any type of cancer. &lt;/p&gt;&lt;hr&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt; &lt;strong&gt;Source: &lt;/strong&gt;Journal of Oral Oncology&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://www.oraloncology.com/article/S1368-8375(12)00297-7/abstract&quot; target=&quot;_blank&quot;&gt;&lt;font color=&quot;#0000ff&quot;&gt; Full Text&lt;/font&gt;&lt;/a&gt;&lt;/p&gt;</abstract_fa>
	<abstract></abstract>
	<keyword_fa>Head and neck cancer, Intratumor heterogeneity, Tumor biomarkers, Next-generation DNA sequencing, Somatic mutations, TP53, Human papillomavirus, Cigarette smoking</keyword_fa>
	<keyword></keyword>
	<start_page>0</start_page>
	<end_page>0</end_page>
	<web_url>http://idai.ir/browse.php?a_code=A-10-32-2447&amp;slc_lang=fa&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Edmund</first_name>
	<middle_name></middle_name>
	<last_name> A. Mroz</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460011632</code>
	<orcid>100319475328460011632</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Center for Cancer Research and Department of Surgery, Massachusetts General Hospital, Boston, MA, United States</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>James</first_name>
	<middle_name></middle_name>
	<last_name> W. Rocco</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460011633</code>
	<orcid>100319475328460011633</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Center for Cancer Research and Department of Surgery, Massachusetts General Hospital, Boston, MA, United States</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
